Skip to main content
Premium Trial:

Request an Annual Quote

Revenues and Earnings up for ABI in Q3 of FY2004

NEW YORK, April 27 (GenomeWeb News) - Applied Biosystems reported increased revenues and earnings for its fiscal year 2004 third quarter today.

 

Revenues for the quarter were $439.6 million, up from $409.4 million during the same quarter last year.

 

Revenues in different product categories were as follows (year-ago revenues in brackets): DNA sequencing $137.5 million ($143.6 million), SDS and other applied genomics $111.6 million ($86.8 million), mass spectrometry $109.4 million ($93.3 million), core DNA synthesis and PCR $50.2 million ($50.7 million), other product lines $30.9 million ($35 million).

 

R&D spending decreased to $57.1 million, from $60 million during the year-ago period.

 

ABI's net earnings for the quarter were $46 million, or $.22 per share, up from $40.1 million, or $.19 per share, during the same period last year.

 

The company, a unit of Applera, did not include its assets in its financial statement.

 

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.